CD8A and melanoma: In agreement with the results from melanoma tumor model (Fig. 3b), ADAM17 deficiency in T cells showed a superior anti-tumor activity than WT controls (Fig. 5n and supplementary Fig. 8d), which also demonstrated an intrinsic role of ADAM17 in CD8+ T cell function.